BMO Capital Starts ARMO BioSciences, Inc. (ARMO) at Outperform

BMO Capital initiates coverage on ARMO BioSciences, Inc. (NASDAQ: ARMO) with a Outperform rating and a price target of $75.00.

Analyst Matt Luchini comments "We believe PDAC Phase III go/no-go interim update (late 1Q/early 2Q) provides near-term de-risking event, while initial Phase II NSCLC response data (late 2018/early 2019) should build on encouraging Phase I results and support AM0010’s blockbuster potential. We leave potential label expansion (second-line NSCLC, RCC) and the pipeline as upside."

For an analyst ratings summary and ratings history on ARMO BioSciences, Inc. click here. For more ratings news on ARMO BioSciences, Inc. click here.

Shares of ARMO BioSciences, Inc. closed at $53.65 Friday.

You May Also Be Interested In

• BMO Capital Starts Alnylam Pharmaceuticals (ALNY) at Outperform
• BMO Capital Starts Bicara Therapeutics Inc (BCAX) at Outperform
• Klarna (KLAR) PT Lowered to $15 at BMO Capital